77 related articles for article (PubMed ID: 14978790)
1. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples.
Mueller RE; Parkes RK; Andrulis I; O'Malley FP
Genes Chromosomes Cancer; 2004 Apr; 39(4):288-97. PubMed ID: 14978790
[TBL] [Abstract][Full Text] [Related]
2. Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Press MF; Sauter G; Buyse M; Bernstein L; Guzman R; Santiago A; Villalobos IE; Eiermann W; Pienkowski T; Martin M; Robert N; Crown J; Bee V; Taupin H; Flom KJ; Tabah-Fisch I; Pauletti G; Lindsay MA; Riva A; Slamon DJ
J Clin Oncol; 2011 Mar; 29(7):859-67. PubMed ID: 21189395
[TBL] [Abstract][Full Text] [Related]
3. High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer.
Staaf J; Jönsson G; Ringnér M; Vallon-Christersson J; Grabau D; Arason A; Gunnarsson H; Agnarsson BA; Malmström PO; Johannsson OT; Loman N; Barkardottir RB; Borg A
Breast Cancer Res; 2010; 12(3):R25. PubMed ID: 20459607
[TBL] [Abstract][Full Text] [Related]
4. Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis.
Ren L; Liu J; Gou K; Xing C
J Cancer; 2018; 9(12):2082-2092. PubMed ID: 29937926
[No Abstract] [Full Text] [Related]
5. In Silico and In Vitro Studies of Novel Azomethines on DNA Repair Genes in Gastric Cell Lines.
Ozturk A; Agbektas T; Huseynzada A; Guliyev R; Ganbarova R; Hasanova U; Tas A; Erkan S; Zontul C; Inandiklioglu N; Silig Y
Life (Basel); 2023 Sep; 13(10):. PubMed ID: 37895364
[TBL] [Abstract][Full Text] [Related]
6. A careful reassessment of anthracycline use in curable breast cancer.
Hurvitz SA; McAndrew NP; Bardia A; Press MF; Pegram M; Crown JP; Fasching PA; Ejlertsen B; Yang EH; Glaspy JA; Slamon DJ
NPJ Breast Cancer; 2021 Oct; 7(1):134. PubMed ID: 34625570
[TBL] [Abstract][Full Text] [Related]
7. Assessment of
Ferreira D; Soares M; Correia J; Adega F; Ferreira F; Chaves R
Aging (Albany NY); 2019 Jul; 11(13):4688-4705. PubMed ID: 31301170
[TBL] [Abstract][Full Text] [Related]
8. Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.
Liu T; Zhang H; Yi S; Gu L; Zhou M
Mol Oncol; 2019 May; 13(5):1047-1058. PubMed ID: 30672125
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer.
Shigematsu H; Ozaki S; Yasui D; Yamamoto H; Zaitsu J; Taniyama D; Saitou A; Kuraoka K; Hirata T; Taniyama K
Oncotarget; 2018 Jun; 9(42):26701-26710. PubMed ID: 29928479
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
An X; Xu F; Luo R; Zheng Q; Lu J; Yang Y; Qin T; Yuan Z; Shi Y; Jiang W; Wang S
BMC Cancer; 2018 Mar; 18(1):331. PubMed ID: 29587760
[TBL] [Abstract][Full Text] [Related]
11. Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.
Dai X; Xiang L; Li T; Bai Z
J Cancer; 2016; 7(10):1281-94. PubMed ID: 27390604
[TBL] [Abstract][Full Text] [Related]
12. Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα.
Nogi H; Uchida K; Kamio M; Kato K; Toriumi Y; Akiba T; Morikawa T; Suzuki M; Kobayashi T; Takeyama H
Mol Clin Oncol; 2016 Mar; 4(3):383-389. PubMed ID: 26998288
[TBL] [Abstract][Full Text] [Related]
13. Screening feature genes of lung carcinoma with DNA microarray analysis.
Chen L; Zhuo D; Chen J; Yuan H
Int J Clin Exp Med; 2015; 8(8):12161-71. PubMed ID: 26550126
[TBL] [Abstract][Full Text] [Related]
14. Comparing two assays for clinical genomic profiling: the devil is in the data.
Squillace RM; Frampton GM; Stephens PJ; Ross JS; Miller VA
Onco Targets Ther; 2015; 8():2237-42. PubMed ID: 26346763
[No Abstract] [Full Text] [Related]
15. Multi-platform profiling of over 2000 sarcomas: identification of biomarkers and novel therapeutic targets.
Movva S; Wen W; Chen W; Millis SZ; Gatalica Z; Reddy S; von Mehren M; Van Tine BA
Oncotarget; 2015 May; 6(14):12234-47. PubMed ID: 25906748
[TBL] [Abstract][Full Text] [Related]
16. TOP2A amplification and overexpression in hepatocellular carcinoma tissues.
Panvichian R; Tantiwetrueangdet A; Angkathunyakul N; Leelaudomlipi S
Biomed Res Int; 2015; 2015():381602. PubMed ID: 25695068
[TBL] [Abstract][Full Text] [Related]
17. The Pathological Response to Anthracycline is Associated with Topoisomerase IIα Gene Amplification in the HER2 Breast Cancer Subset.
Ishikawa T; Sasaki T; Tanabe M; Narui K; Kida K; Shimada K; Shimizu D; Yamada A; Morita S; Oba MS; Kawachi K; Nozawa A; Ichikawa Y; Takabe K; Endo I
J Surg Sci; 2014 Dec; 2(1):10-12. PubMed ID: 25642443
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIα in chromosome instability and personalized cancer therapy.
Chen T; Sun Y; Ji P; Kopetz S; Zhang W
Oncogene; 2015 Jul; 34(31):4019-31. PubMed ID: 25328138
[TBL] [Abstract][Full Text] [Related]
19. TOP2A overexpression as a poor prognostic factor in patients with nasopharyngeal carcinoma.
Lan J; Huang HY; Lee SW; Chen TJ; Tai HC; Hsu HP; Chang KY; Li CF
Tumour Biol; 2014 Jan; 35(1):179-87. PubMed ID: 23897556
[TBL] [Abstract][Full Text] [Related]
20. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.
de Resende MF; Vieira S; Chinen LT; Chiappelli F; da Fonseca FP; Guimarães GC; Soares FA; Neves I; Pagotty S; Pellionisz PA; Barkhordarian A; Brant X; Rocha RM
J Transl Med; 2013 Feb; 11():36. PubMed ID: 23398928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
